News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
293,645 Results
Type
Article (18647)
Company Profile (319)
Press Release (274679)
Section
Business (86248)
Career Advice (235)
Deals (14284)
Drug Delivery (32)
Drug Development (58442)
Employer Resources (38)
FDA (6782)
Job Trends (6118)
News (161062)
Policy (12345)
Tag
Academia (1275)
Alliances (23587)
Alzheimer's disease (805)
Approvals (6729)
Artificial intelligence (66)
Bankruptcy (110)
Best Places to Work (5405)
Biotechnology (263)
Breast cancer (63)
Cancer (690)
Cardiovascular disease (53)
Career advice (191)
CAR-T (54)
Cell therapy (169)
Clinical research (45556)
Collaboration (222)
Compensation (96)
COVID-19 (1853)
C-suite (55)
Cystic fibrosis (64)
Data (680)
Diabetes (69)
Diagnostics (1542)
Earnings (31122)
Events (51647)
Executive appointments (164)
FDA (7051)
Funding (220)
Gene editing (49)
Gene therapy (133)
GLP-1 (305)
Government (1741)
Healthcare (7768)
Infectious disease (1914)
Inflammatory bowel disease (96)
IPO (7823)
Job creations (979)
Job search strategy (184)
Layoffs (205)
Legal (1554)
Lung cancer (129)
Manufacturing (74)
Medical device (2711)
Medtech (2712)
Mergers & acquisitions (6540)
Metabolic disorders (214)
Neuroscience (997)
NextGen Class of 2024 (2266)
Non-profit (1129)
Northern California (851)
Obesity (122)
Opinion (94)
Parkinson's disease (57)
Patents (54)
People (26677)
Pharmaceutical (53)
Phase I (15849)
Phase II (20959)
Phase III (13782)
Pipeline (157)
Postmarket research (1067)
Preclinical (6687)
Radiopharmaceuticals (206)
Rare diseases (147)
Real estate (1575)
Regulatory (9782)
Research institute (1307)
Southern California (772)
Startups (2054)
United States (7287)
Vaccines (464)
Weight loss (77)
Date
Today (149)
Last 7 days (556)
Last 30 days (2013)
Last 365 days (22843)
2024 (19510)
2023 (24968)
2022 (30103)
2021 (31800)
2020 (27182)
2019 (18453)
2018 (13496)
2017 (15592)
2016 (13582)
2015 (16246)
2014 (11737)
2013 (8491)
2012 (8557)
2011 (8517)
2010 (8206)
Location
Africa (208)
Asia (19027)
Australia (3367)
California (1928)
Canada (689)
China (142)
Colorado (73)
Connecticut (75)
Europe (41375)
Florida (213)
Georgia (57)
Illinois (121)
Indiana (84)
Kansas (55)
Maryland (299)
Massachusetts (1623)
Michigan (46)
Minnesota (85)
New Jersey (565)
New York (611)
North Carolina (397)
Northern California (851)
Ohio (76)
Pennsylvania (395)
South America (257)
Southern California (772)
Texas (204)
Washington State (221)
293,645 Results for "immune therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Gnubiotics Secures Key Composition of Matter Patents for Obesity, Diabetes, and Immune-Related Diseases, Strengthening Its Glycopeptide Therapeutics Platform
October 8, 2024
·
1 min read
Biotech Bay
Immune-Onc Therapeutics Announces Presentation of IO-202 Phase 1b Interim Data of Patients with Chronic Myelomonocytic Leukemia (CMML) at 2024 European Hematology Association (EHA) Annual Congress
Immune-Onc Therapeutics, Inc. (“Immune-Onc”) today announced the company will present Phase 1b interim data for IO-202 in patients with chronic myelomonocytic leukemia (CMML) at the 2024 European Hematology Association (EHA) Annual Meeting held virtually and in Madrid, Spain, June 13 – 16.
May 14, 2024
·
5 min read
Drug Development
Immune-Onc Therapeutics to Present Additional Positive Interim Data from IO-202 Phase 1b Expansion Cohort in Patients with Chronic Myelomonocytic Leukemia (CMML) at 2024 European Hematology Association (EHA) Annual Congress
Immune-Onc Therapeutics, Inc. announced the company will present additional positive interim Phase 1b expansion cohort data for IO-202 in patients with chronic myelomonocytic leukemia at the 2024 European Hematology Association Annual Meeting held virtually and in Madrid, Spain, June 13 – 16.
June 14, 2024
·
6 min read
Defence’s AccuTOX Boosts and Synergizes with Immune Checkpoint Inhibitors
Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) (“Defence” or the “Company”), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is please to announce that Defence’s Accum-002TM (“AccuTOX®") has different mode
July 1, 2024
·
5 min read
Genetown
Conformation-X Therapeutics Bolts out of Stealth, Securing Over $13.5M in Funding to Propel Its Innovative Immune-Oncology Pipeline
Conformation-X Therapeutics, LLC, an immune-oncology focused drug development company, announced that it has closed an oversubscribed funding tranche of $3.65M, bringing the total raised since inception to over $13.5M.
April 3, 2024
·
4 min read
Pharm Country
LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
LAVA Therapeutics N.V. today announced that Stephen Hurly, President and Chief Executive Officer of LAVA Therapeutics, will present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference.
June 20, 2024
·
1 min read
Olink® Target 48 Immune Surveillance Panel – The Next Frontier in Immune Biomarker Profiling with Absolute Confidence
Olink Holding AB announced the introduction of Olink Target 48 Immune Surveillance, a validated multiplexed protein assay panel that offers a detailed view of the immune system for in-depth monitoring of inflammation and immune response in clinical research.
June 6, 2024
·
5 min read
Biotech Bay
Immune-Onc Therapeutics Announces Orphan Drug Designation Granted by US FDA for IO-202 (Anti-LILRB4) for the Treatment of Chronic Myelomonocytic Leukemia (CMML)
Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a clinical-stage biopharmaceutical company advancing novel therapies in immunology and oncology by targeting myeloid cell inhibitory receptors, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for IO-202 for the treatment of chronic myelomonocytic leukemia (CMML).
February 21, 2024
·
6 min read
Drug Development
Immune-Onc Therapeutics Announces Clinical Trial Collaboration to Evaluate IO-108 in a Randomized Global Phase 1b/2 Study for First-Line Treatment of Advanced Liver Cancer
Immune-Onc Therapeutics, Inc. (“Immune-Onc”) today announced a Phase 1b/2 clinical trial collaboration with Roche to evaluate Immune-Onc’s IO-108, a first-in-class antibody targeting LILRB2 (also known as ILT4), in combination with Roche’s atezolizumab and bevacizumab for the first-line treatment of patients with locally advanced or metastatic and/or unresectable hepatocellular carcinoma (HCC).
February 20, 2024
·
6 min read
Biotech Bay
CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference on Tuesday, June 25, 2024, at 2:00 p.m. ET.
June 18, 2024
·
2 min read
1 of 29,365
Next